Compare ACADIA Pharmaceuticals Inc. (ACAD) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.56. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ACAD | YMAG | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $28.06 | $15.98 |
52-Week Low | $20.06 | $11.00 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.70, up 2.01% today, but technical indicators signal bearish momentum with resistance at $12. The ETF maintains weekly dividend distributions, though recent analysis highlights concerns about NAV decay from its synthetic covered call strategy on Magnificent Seven stocks. Mixed sentiment prevails with some analysts seeing tactical opportunities in rangebound markets while others cite limited upside potential.
Outlook remains cautious due to structural NAV erosion risks and high expense ratios. The fund's performance depends heavily on volatility monetization from its underlying option strategy, creating both income opportunities and capital depreciation risks in trending markets. Investors should weigh the high yield against potential long-term underperformance versus the broader market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
